Skip to main content

Table 1 Main clinicopathological features of Study Group 1

From: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

Variable

Study Group 1

(n = 152)

Age:

 Mean age ± SEM

65 ± 0.81

 Range

41–85

pTNM stage:

 Stage I

20 (13.2%)

 Stage II

11 (7.2%)

 Stage III

111 (73%)

 Stage IV

10 (6.6%)

Debulking

 R0

75 (49.4%)

 R1

12 (7.9%)

 R2

65 (42.7%)

Vital status of patients

70 (46.1%)

Back to article page